Prediction of the Short-Term Effectiveness of Ustekinumab in Patients with Moderate to Severe Crohn’s Disease
Tao Su,1,2,* Ling Liu,3,* Fan Meng,4,* Hongzhen Wu,1,2 Tao Liu,1,2 Jun Deng,1,2 Xiang Peng,1,2 Min Zhi,1,2 Jiayin Yao1,2 1Department of Gastroenterology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital, Sun Yat-Sen Uni...
Saved in:
Main Authors: | Su T (Author), Liu L (Author), Meng F (Author), Wu H (Author), Liu T (Author), Deng J (Author), Peng X (Author), Zhi M (Author), Yao J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2024-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical utility of ustekinumab in Crohn’s disease
by: Kotze PG, et al.
Published: (2018) -
Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy
by: Deepak P, et al.
Published: (2016) -
Enfermedad de Crohn metastásica tratada con ustekinumab
by: Rosa Ballester Sánchez, et al.
Published: (2021) -
Refractory metastatic Crohn's disease responsive to ustekinumab dose intensification
by: Teresa L. Xiao, BA, et al.
Published: (2023) -
Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes
by: Horst S, et al.
Published: (2023)